Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

a study on Prostate Cancer

Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Daniel Kwon, MD (ucsf)

Description

Summary

The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the tool for implementation.

Official Title

Developing and Testing a Patient-centered Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Metastatic Prostate Cancer

Details

PRIMARY OBJECTIVES:

Stage 1: To evaluate education quality of the intervention in Black or African American men with prostate cancer.

Stage 2: To evaluate feasibility of the TGT intervention among Black or African American men with prostate cancer

SECONDARY OBJECTIVES:

Stage 1:

  1. To evaluate completeness of the intervention content.
  2. To identify barriers and facilitators for using the intervention.

Stage 2:

  1. To evaluate the acceptability of the intervention among Black or African American men with prostate cancer.
  2. To evaluate change in participant knowledge about tumor genetic testing among Black or African American men with prostate cancer.
  3. To evaluate change in patient attitudes toward tumor genetic testing among Black or African American men with prostate cancer.
  4. To evaluate change in participant expectations of tumor genetic testing among Black or African American men with prostate cancer.
  5. To evaluate patient perspectives on the intervention.
  6. To evaluate the rate of TGT among Black or African American men with prostate cancer who have received the tumor genetic pre-test counseling tool.

OUTLINE:

This is a two-stage study. In Stage 1, Adult Black or African American men with metastatic prostate cancer who have not made a decision about TGT, or who have decided to undergo TGT, or patients who have decline TGT about tumor genetic testing will participate in development by answering questionnaires and utilizing the pilot application for up to 60 days. The investigators will then refine the tool to be piloted in Stage 2.

Stage 2: A pilot study of participants who are planning to have a discussion about undergoing tumor genetic testing with their oncology provider will be invited to join and utilize the tool, and answer questionnaires about the tool.

Keywords

Prostate Cancer, Prostate Cancer Metastatic, Prostatic Neoplasms, Surveys and Questionnaires

Eligibility

You can join if…

Open to males ages 18 years and up

Stage 1:

  1. Age 18-years-old or older
  2. Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race including Black or African American is included.
  3. Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
  4. Able to understand study procedures and to comply with them for the entire length of the study.
  5. Able to understand a written information sheet and willing to verbally consent.
  6. Fluent in English (reading, writing, and speaking)

Stage 2:

  1. Age 18-years-old or older
  2. Identifies as Black or African-American, by either chart documentation or participant self-report. Mixed-race including Black or African-American is included.
  3. Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
  4. Able to understand study procedures and to comply with them for the entire length of the study.
  5. Fluent in English (reading, writing, and speaking).
  6. Anticipated discussion of TGT within 0-90 days of enrollment, per treating oncology provider's discretion. TGT involves use of any cancer genetic sequencing (whether standard-of-care or part of a research protocol) via any one of the following:
    1. Somatic DNA testing of already-collected tissue.
    2. Somatic DNA testing of tissue to be collected in the future via biopsy, surgery, or other procedure.
    3. Blood-based DNA testing to evaluate for circulating tumor DNA.
  7. Able to understand a written informed consent document and willing to sign it.

You CAN'T join if...

Contraindication to any study-related procedure or assessment in either stage.

Location

  • University of California accepting new patients
    San Francisco 5391959 California 5332921 94143 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT06171139
Study Type
Interventional
Participants
Expecting 80 study participants
Last Updated